Wellington Management Group LLP Has $520,000 Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Wellington Management Group LLP lowered its position in shares of Catalent, Inc. (NYSE:CTLT) by 10.3% in the third quarter, HoldingsChannel reports. The firm owned 8,585 shares of the company’s stock after selling 990 shares during the period. Wellington Management Group LLP’s holdings in Catalent were worth $520,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Brooklyn Investment Group acquired a new position in Catalent in the third quarter worth $31,000. Sentry Investment Management LLC bought a new position in shares of Catalent in the third quarter valued at about $53,000. Longfellow Investment Management Co. LLC lifted its position in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its holdings in Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in Catalent in the 3rd quarter valued at about $73,000.

Catalent Price Performance

Shares of CTLT stock opened at $63.48 on Friday. The firm’s 50 day moving average price is $60.58 and its two-hundred day moving average price is $59.30. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent, Inc. has a 52-week low of $41.15 and a 52-week high of $63.50. The stock has a market cap of $11.52 billion, a PE ratio of -28.09, a PEG ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the business earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. As a group, analysts forecast that Catalent, Inc. will post 0.78 EPS for the current year.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CTLT has been the topic of a number of research reports. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a report on Tuesday, December 10th. Robert W. Baird reissued a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.